The Asia Pacific Congestive Heart Failure (CHF) Treatment Devices Market would witness market growth of 5.9% CAGR during the forecast period (2022-2028).
CRT is used to treat patients who have aberrant electrical and mechanical activation, which leads to increased cardiac inefficiency and performance. On an ECG, aberrant electrical activation is indicated by a prolonged QRS duration and, in most cases, left bundle branch block. Desynchrony is an abnormal activation pattern that can be intraventricular, interventricular, or atrioventricular. CRT's atrial synchronized pacing from the right and left ventricles allows this cardiac desynchrony to be corrected and cardiac function to be improved. With the rising number of people with cardiac disorders and illnesses, the demand for congestive heart failure treatment devices is estimated to spur in the coming years.
Many ICDs and CRTs have built-in technologies that allow the doctor or nurse to monitor patients' heart function, heart rhythm, and amount of exercise. In addition, the patient may need to use a personal digital assistant to convey information to their healthcare physician. The modern internal monitoring device (CardioMEMS) is as small as a paperclip. It is implanted in a blood vessel near the heart to monitor blood vessel and left ventricular pressure. The data is transmitted to a computer server. The healthcare practitioner utilizes the data from the device to make sure that the patient is receiving the optimum therapy for the disease and to determine if they need to modify anything about their medication, food, or amount of activity.
Over the past few years, China has witnessed significant and fundamental transformations. As a result of lifestyle modifications, urbanization, and the hastened aging process, China is experiencing cardiovascular disease (CVD) crisis. CVDs are on the rise and will continue to do so during the next few years. Since 2005, the Chinese National Center for Cardiovascular Diseases has brought together experts in cardiology, nephrology, neurology, diabetes, epidemiology, health economics, biostatistics, and other domains to write the annual Report on Cardiovascular Diseases in China. The goal of the study is to give a timely analysis of the expanding CVD outbreaks as well as an assessment of CVD prevention and control measures. A summary of the Report on Cardiovascular Diseases in China 2015 is provided, which contains trends in CVD, CVD morbidity and mortality, risk factors evaluation, CVD health resources, and a medical cost profile.
The China market dominated the Asia Pacific Congestive Heart Failure (CHF) Treatment Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,300.2 Million by 2028. The Japan market is estimated to grow at a CAGR of 5.3% during (2022 - 2028). Additionally, The India market would witness a CAGR of 6.6% during (2022 - 2028).
Based on Product Type, the market is segmented into Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Congestive Heart Failure (CHF) Treatment Devices Market is Projected to reach USD 16.5 Billion by 2028, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
